Real-time SEC alerts Start Free →
Profitelligence
Iqvia Holdings Inc.
IQV MEDIUM Impact

Iqvia Holdings Inc.

IQVIA Announces $2 Billion Increase in Share Repurchase Authorization

| 8-K |Healthcare

Summary

IQVIA Holdings Inc. announced on May 7, 2026, that its board of directors has authorized an additional $2 billion for the repurchase of the company's common stock under its existing equity repurchase program. This increase brings the total remaining authorization to $3.2 billion. The repurchase program, which does not obligate the company to repurchase any particular amount of stock, may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases are determined by the company's management based on various factors including market price, corporate requirements, and market conditions. Purchases may be made in open market transactions, block trades, or privately negotiated transactions. The program has no expiration date, and the company may also repurchase stock through private or other transactions outside of the program. IQVIA may discontinue repurchases without notice at any time.

Profitelligence Profitelligence Alerts

Get alerts for IQV

Be first to know when Iqvia Holdings Inc. files with the SEC.

Set Up Alerts →

Filing Categories

Share Repurchase Program Announced Financial Instrument Agreement

Advertisement

About Iqvia Holdings Inc.

Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.

Exchange: NYSE Industry: Diagnostics & Research Company Website →

Official SEC Documents

IQV
IQV Research
8Ks, insider trades, financials, technicals
SEC Alert Manager
Get alerts within 60 seconds of new filings

Advertisement